Eli Lilly Signs an Agreement with Banner Alzheimer's Institute to Evaluate Donanemab in P-III TRAILBLAZER-ALZ 3 Trial for Alzheimer's Disease
Shots:
- The collaboration is a part of the planned P-III TRAILBLAZER-ALZ 3 trial of donanemab vs PBO in patients with cognitive & functional decline related to AD. The study will assess if therapy slows the clinical progression of AD
- Banner will support the enrollment of trial participants with & without e4 type of APOE4 gene through Alzheimer's Prevention Registry's GeneMatch program. Lilly will be sole sponsor of study and expect to start the enrollment in 2021
- Donanemab is an investigational Ab that targets a modified form of beta-amyloid. The therapy is being evaluated in the ongoing P-III TRAILBLAZER-ALZ 2 study for early- symptomatic AD
Ref: PR Newswire | Image: Eli Lilly
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com